Drug Name:
Cyclophosphamide Injection Rx

Generic Name and Formulations:
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Company:
Various generic manufacturers
Therapeutic Use:
Indications for Cyclophosphamide Injection:
Carcinoma of the breast.
Adult:
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children:
See full labeling.
Contraindications:
Severe bone marrow depression.
Warnings/Precautions:
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions:
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
See Also:
Pharmacological Class:
Alkylating agent.
Adverse Reactions:
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Note:
Formerly known under the brand name Cytoxan.
How Supplied:
Contact supplier
Indications for Cyclophosphamide Injection:
Neuroblastoma (disseminated disease).
Adult:
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children:
See full labeling.
Contraindications:
Severe bone marrow depression.
Warnings/Precautions:
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions:
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
See Also:
Pharmacological Class:
Alkylating agent.
Adverse Reactions:
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Note:
Formerly known under the brand name Cytoxan.
How Supplied:
Contact supplier
Indications for Cyclophosphamide Injection:
Retinoblastoma.
Adult:
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children:
See full labeling.
Contraindications:
Severe bone marrow depression.
Warnings/Precautions:
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions:
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
See Also:
Pharmacological Class:
Alkylating agent.
Adverse Reactions:
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Note:
Formerly known under the brand name Cytoxan.
How Supplied:
Contact supplier
Indications for Cyclophosphamide Injection:
Adenocarcinoma of the ovary.
Adult:
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children:
See full labeling.
Contraindications:
Severe bone marrow depression.
Warnings/Precautions:
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions:
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
See Also:
Pharmacological Class:
Alkylating agent.
Adverse Reactions:
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Note:
Formerly known under the brand name Cytoxan.
How Supplied:
Contact supplier
Indications for Cyclophosphamide Injection:
Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma. Multiple myeloma. Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease).
Adult:
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children:
See full labeling.
Contraindications:
Severe bone marrow depression.
Warnings/Precautions:
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Interactions:
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
See Also:
Pharmacological Class:
Alkylating agent.
Adverse Reactions:
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Note:
Formerly known under the brand name Cytoxan.
How Supplied:
Contact supplier
Sign Up for Free e-newsletters
ONA Articles
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- Breast Cancer Treatment-Related Financial Burden Greater for Black vs White Women
- Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Olanzapine Use to Prevent Chemotherapy-Induced Nausea and Vomiting
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Intervention Improves Body Image-Related Distress in Survivors of Breast Cancer
- Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT
- Cancer Survivors May be More Prone to Polypharmacy
- Too Much Information: When Prognosis Breaks Down Patient Communications
- Breast Cancer Treatment-Related Financial Burden Greater for Black vs White Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |